ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Los Angeles, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Los Angeles, CA, USA:

RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma.The drugs invo...

Active, not recruiting
Follicular Lymphoma
Drug: Avelumab
Drug: PF04518600

Phase 1

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Duarte, California, United States and 5 other locations

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Enrolling
Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

Duarte, California, United States and 6 other locations

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research.Adults with non-Hodgkin lymphoma...

Active, not recruiting
Lymphoma, Malignant
Non-hodgkin Lymphoma
Drug: DS-3201b

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Duarte, California, United States and 20 other locations

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: HMPL-523

Phase 1

HUTCHMED
HUTCHMED

Downey, California, United States and 31 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Los Angeles, California, United States and 89 other locations

multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma...

Active, not recruiting
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Drug: Capivasertib

Phase 2

AstraZeneca
AstraZeneca

Los Angeles, California, United States and 16 other locations

Locations recently updated

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Los Angeles, California, United States and 66 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Downey, California, United States and 31 other locations

1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for whic...

Enrolling
Lymphoma
Solid Tumor, Adult
Drug: Fadraciclib

Phase 1, Phase 2

Cyclacel Pharmaceuticals

Duarte, California, United States and 3 other locations

in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question t...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Radiation: External-beam radiotherapy (XRT)
Biological: SIRPant-M

Phase 1

SIRPant Immunotherapeutics

Duarte, California, United States and 2 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems